Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World.
For the patients presenting a NSCLC stage IV, the median of survival is about 15 months
today. The chemotherapy with platinum is the standard treatment for these patients but
immunotherapy showed these efficacy in 1st line for patients PD-L1 positive. On the other
hand, the duration of treatment by immunotherapy is not clear. Indeed, prolonged responses
and long survivals have been described in patients having interrupted the treatment. In the
melanoma, a treatment of 6 months of ipilimumab demonstrated its efficacy. The objective of
the study is to demonstrate that a treatment of 6 months followed by an observation (stop and
go) is not less effective than a treatment given until progression or toxicity. This strategy
would allow to decrease the accumulated toxicities, to improve the quality of life of the
patients and to decrease the costs.
Non Small Cell Lung Cancer Metastatic
Clinical Study Identifier
Intergroupe Francophone de Cancerologie Thoracique
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.